CN112263671A - Compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV - Google Patents

Compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV Download PDF

Info

Publication number
CN112263671A
CN112263671A CN202011062684.XA CN202011062684A CN112263671A CN 112263671 A CN112263671 A CN 112263671A CN 202011062684 A CN202011062684 A CN 202011062684A CN 112263671 A CN112263671 A CN 112263671A
Authority
CN
China
Prior art keywords
hbv
ncov
parts
compound preparation
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202011062684.XA
Other languages
Chinese (zh)
Inventor
朱洪滨
盛晓春
徐俊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202011062684.XA priority Critical patent/CN112263671A/en
Publication of CN112263671A publication Critical patent/CN112263671A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the technical field of biology, in particular to a compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV, which comprises the following components in parts by mass: 8-12 parts of nicotinamide mononucleotide, 2-6 parts of chlorogenic acid, 2-6 parts of echinacea purpurea extract and 1-3 parts of glutathione. The compound preparation can effectively inhibit HIV, HBV, H1N1, H3N2 and nCoV, can effectively improve the autoimmune system, can stop taking at any time, has no side effect, does not cause HIV, HBV, H1N1, H3N2 or nCoV to be actively copied after the taking is stopped, reduces the damage to body organs and slows down the disease deterioration.

Description

Compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV
Technical Field
The invention relates to the technical field of biology, in particular to a compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV.
Background
AIDS is a short term for acquired immunodeficiency syndrome, and is a chronic infectious disease caused by Human Immunodeficiency Virus (HIV). The disease is mainly transmitted by sexual contact, blood and mother and baby. HIV mainly invades and destroys CD4+ T lymphocytes, resulting in impairment or even defect of immune cells and/or functions of the body, and finally, merging of various severe opportunistic infections and tumors. Has the characteristics of rapid propagation, slow disease onset and high disease death rate.
Hepatitis B virus is called hepatitis B virus for short. Is a DNA virus belonging to the hepadnaviridae. As is known, HBV is only susceptible to humans and orangutan, causing viral hepatitis B. The whole hepatitis B virus is in the form of granules, which will also be called Dana granules (Dane). Hepatitis B Virus (HBV) belongs to the family of hepadnaviridae, and the genome is about 3.2kb in length and is a partially double-stranded circular DNA. HBV is strongly resistant, but HBV can be inactivated by 10 hours at 65 ℃, 10 minutes after boiling or high-pressure steam. Chlorine-containing preparations, ethylene oxide, glutaraldehyde, peracetic acid, iodophor and the like also have good inactivation effect.
H1N1 is one of influenza a viruses, RNA viruses, and belongs to the orthomyxoviridae family. Its host is birds and some mammals, and some species of H1N1 can be transmitted between humans. By "H1N 1" is meant the abbreviation for the viral name, with "H" referring to hemagglutinin and "N" referring to neuraminidase, both of which are the antigenic names on the virus.
Influenza A H3N2 is a respiratory disease caused by myxovirus, can be transmitted through respiratory tracts of various animals (dogs, chickens, ducks and the like), and patients mostly show symptoms of common influenza, sometimes diarrhea and vomiting, and serious patients can have secondary pneumonia and respiratory failure, even die. The current effective prevention is vaccination.
Pneumonia of new coronavirus infection is lung inflammation caused by new coronavirus (nCoV) infection, and the WHO names the new coronavirus of this time as 2019-nCoV. Clinical needles of patients infected with the novel coronavirus are mainly manifested by fever, weakness and dry cough, and dyspnea can occur in severe patients. It also causes complications such as acute respiratory distress syndrome, septic shock, metabolic acidosis, and blood coagulation dysfunction, and leads to death of infected persons.
When patients infected with HIV, HBV, H1N1, H3N2 or nCoV are treated, antiviral drugs are required to be taken, the commonly used antiviral drugs are lamivudine, adefovir, entecavir, tenofovir disoproxil fumarate and the like, the antiviral drugs have certain toxic and side effects and cannot be stopped at will, if the patients stop at will, viruses are easy to replicate and activate, body organs are seriously damaged, and the deterioration of the state of an illness is accelerated.
Therefore, we propose a complex formulation that can effectively inhibit HIV, HBV, H1N1, H3N2 and nCoV to solve the above problems.
Disclosure of Invention
The invention aims to overcome the defects that the existing antiviral drugs in the prior art have certain side effects and cannot be stopped randomly, and provides a compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV, which achieves the following technical effects briefly.
In order to achieve the purpose, the invention adopts the following technical scheme:
a compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV comprises the following components in parts by mass: 8-12 parts of nicotinamide mononucleotide, 2-6 parts of chlorogenic acid, 2-6 parts of echinacea purpurea extract and 1-3 parts of glutathione.
Further, the echinacea purpurea extract is chicoric acid.
Further, the nicotinamide mononucleotide is a product of nicotinamide phosphoribosyltransferase reaction, is one of key precursors of NAD +, and is used for delaying aging of organs in the body, increasing the vitality of the organs and improving the autoimmune system.
Nicotinamide mononucleotide plays an important role in the cellular energy production of the human body, and it is involved in the synthesis of intracellular NAD (nicotinamide adenine dinucleotide, an important coenzyme for cellular energy conversion), which is an important coenzyme for cellular energy conversion. Can recover the damage of human DNA cells and activate the human DNA cells, and improve the life span of the human DNA cells, thereby prolonging the life span of the human body.
In addition, nicotinamide mononucleotide can promote the biosynthesis of NAD + to be up-regulated, in fact, DNA damage and prevention of function decline caused by the reduction of NAD + level are key causes of cancer, and the slowing of the aging rate of the body can prevent the generation of tumors to a certain extent, so the nicotinamide mononucleotide also has the function of cancer resistance and is beneficial to prolonging the life of a human body.
Furthermore, the chlorogenic acid has good antiviral property on HIV, HBV, H1N1, H3N2 and nCoV.
The chlorogenic acid can well inhibit HIV-1 integrase.
The chlorogenic acid can inhibit infection of H1N1 and H3N2 by down-regulating the expression of viral nucleoprotein and inhibiting neuraminidase activity.
The chlorogenic acid can also treat viral infections by effectively reducing inflammatory responses and inhibiting viral infection production.
The chlorogenic acid can inhibit HBV by inhibiting HBV-DNA replication and hepatitis B surface protein antigen production.
Further, the chicoric acid has the effect of inhibiting HIV-1 virus and HIV-1 integrase, and is used for inhibiting the spread of HIV virus.
Furthermore, the glutathione not only has the functions of delaying senility and enhancing immunity, but also has the functions of inhibiting HIV virus and HBV virus.
Further, the composite preparation may be one of a tablet, a capsule, or a powder.
Compared with the prior art, the invention has the beneficial effects that:
in the invention, the compound preparation can effectively inhibit HIV, HBV, H1N1, H3N2 and nCoV, can effectively improve the autoimmune system, can stop taking at any time, has no side effect, can not lead to the replication activity of HIV, HBV, H1N1, H3N2 or nCoV after the taking is stopped, reduces the damage to body organs and slows down the disease deterioration.
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments.
A compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV comprises the following components in parts by mass: 8-12 parts of nicotinamide mononucleotide, 2-6 parts of chlorogenic acid, 2-6 parts of echinacea purpurea extract and 1-3 parts of glutathione.
More specifically, the echinacea extract is chicoric acid.
More specifically, the composite preparation may be one of a tablet, a capsule, or a powder.
Example one
Purpose of the experiment: the inhibition of the composite preparation on HBV is measured.
Subject: the 12 patients, 6 male patients and 6 female patients, with the age of 30-35, were hepatitis B virus carriers.
The condition of the patient: the value of hepatitis B virus DNA is 9.09E +2, the hepatitis B surface antigen is more than 0.2ng/mL, the hepatitis B surface antibody is 480IU/L, the hepatitis B E antigen is 0.6-0.7PEIU/mL, the hepatitis B E antibody is 1.02-1.1PEIU/mL, the hepatitis B core antibody is 1.3-1.5PEIU/mL, the median of liver hardness (KPA) is 13.3-13.4, the median of fat attenuation (db/m) is 265 ℃ 295, and the color Doppler ultrasound result is normal.
The experimental method comprises the following steps: selecting male patients No. 1, male patients No. 2 and male patients No. 3, female patients No. 1, female patients No. 2 and female patients No. 3, respectively taking the compound preparation, wherein the taking period is 8 months, in addition, the unselected male patients No. 4, No. 5 and male patients No. 6, male patients No. 3, female patients No. 4, female patients No. 5 and female patients No. 6 do not take any medicine, after the period is finished, the hepatitis B virus amount, the transaminase index, the jaundice index, the median of liver hardness (KPA), the median of fat attenuation (db/m) and the liver color ultrasound of the 12 patients are respectively measured, and the measurement results are as follows:
Figure RE-GDA0002818631970000051
Figure RE-GDA0002818631970000061
in addition, the change of hepatic fibrosis index and liver function index before and after treatment of 6 patients taking the compound preparation is recorded, and the record content is as follows:
Figure RE-GDA0002818631970000071
Figure RE-GDA0002818631970000072
Figure RE-GDA0002818631970000081
Figure RE-GDA0002818631970000082
Figure RE-GDA0002818631970000091
Figure RE-GDA0002818631970000092
Figure RE-GDA0002818631970000101
according to the above table, the complex preparation can inhibit HBV.
Example two
Purpose of the experiment: the inhibition of nCoV by this complex formulation was determined.
Subject: 12 pigs were selected, 6 of which were adult boars and 6 of which were young boars, all infected with the novel coronavirus (nCoV).
The experimental method comprises the following steps: selecting an adult boar No. 1, an adult boar No. 2, an adult boar No. 3, a young boar No. 1, a young boar No. 2 and a young boar No. 3 to take the compound preparation, and taking the compound preparation out of the adult boar No. 4, the adult boar No. 5, the adult boar No. 6, the young boar No. 4, the young boar No. 5 and the young boar No. 6, carrying out the same feeding, recording the survival conditions of 12 pigs, wherein the recording period is 10 days, and the recording is shown in the following table:
Figure RE-GDA0002818631970000102
Figure RE-GDA0002818631970000111
as can be seen from the above table, the complex preparation can inhibit nCoV.
The working principle and the using process of the invention are as follows:
in the invention, the compound preparation can effectively inhibit HIV, HBV, H1N1, H3N2 and nCoV, can effectively improve the autoimmune system, can stop taking at any time, has no side effect, can not lead to the replication activity of HIV, HBV, H1N1, H3N2 or nCoV after the taking is stopped, reduces the damage to body organs and slows down the disease deterioration.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.

Claims (3)

1. A compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV is characterized by comprising the following components in parts by mass: 8-12 parts of nicotinamide mononucleotide, 2-6 parts of chlorogenic acid, 2-6 parts of echinacea purpurea extract and 1-3 parts of glutathione.
2. The combination of claim 1, wherein the Echinacea purpurea extract is chicoric acid, effective in inhibiting HIV, HBV, H1N1, H3N2, and nCoV.
3. The compound preparation for effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV according to claim 1, wherein said compound preparation can be one of tablet, capsule or powder.
CN202011062684.XA 2020-09-30 2020-09-30 Compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV Withdrawn CN112263671A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202011062684.XA CN112263671A (en) 2020-09-30 2020-09-30 Compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202011062684.XA CN112263671A (en) 2020-09-30 2020-09-30 Compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV

Publications (1)

Publication Number Publication Date
CN112263671A true CN112263671A (en) 2021-01-26

Family

ID=74337451

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202011062684.XA Withdrawn CN112263671A (en) 2020-09-30 2020-09-30 Compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV

Country Status (1)

Country Link
CN (1) CN112263671A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018306A (en) * 2021-03-05 2021-06-25 中国人民解放军军事科学院军事医学研究院 Application of nicotinamide mononucleotide in preparing medicine for inhibiting SARS-CoV-2 virus susceptibility
WO2023016389A1 (en) * 2021-08-10 2023-02-16 成都川宇健维生物科技有限公司 COMPOSITION COMPRISING β-NICOTINAMIDE MONONUCLEOTIDE AND CHLOROGENIC ACID, AND APPLICATION THEREOF

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113018306A (en) * 2021-03-05 2021-06-25 中国人民解放军军事科学院军事医学研究院 Application of nicotinamide mononucleotide in preparing medicine for inhibiting SARS-CoV-2 virus susceptibility
WO2023016389A1 (en) * 2021-08-10 2023-02-16 成都川宇健维生物科技有限公司 COMPOSITION COMPRISING β-NICOTINAMIDE MONONUCLEOTIDE AND CHLOROGENIC ACID, AND APPLICATION THEREOF

Similar Documents

Publication Publication Date Title
Hilleman Prospects for the use of double-stranded ribonucleic acid (poly I: C) inducers in man
CN112263671A (en) Compound preparation capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV
CN111135184A (en) Application of GS-441524 in preparation of novel coronavirus SARS-CoV-2 inhibitor
US11752133B2 (en) Use of bromophenol-pyrazoline compounds in the treatment of porcine coronavirus diseases
CN111821310A (en) Rudexiwei preparation and indications thereof
JP2899292B2 (en) Method of treating hepatitis B with antiviral agent
CN112156099A (en) Compound preparation applied to HIV, HBV and nCoV antiviral treatment
JP4556009B2 (en) Anti-inflammatory agents, preventive or ameliorating agents for allergic diseases and functional foods
CN113855654A (en) A composition for preventing and treating coronavirus infection
WO2018093734A1 (en) Method for treating hepatitis b
JPS61109723A (en) Treatment for human viral disease by use of 1-beta-d-ribofuranosyl-1,2,4-triazole-3-carboxamide
CN114259492A (en) Application of nitazoxanide in treating hepatitis B
JP7293225B2 (en) Treatment of RSV with combination products
CN115105519A (en) Pharmaceutical composition for treating hepatitis B and preparation method thereof
CN113662949A (en) Application of N-acetyl-D-mannosamine in preparation of antiviral drugs
CN103070858B (en) Application of benzo Alpha-pyrone compound as Gamma-type human herpes virus-resistant medicine
JP3002700B2 (en) Anti-AIDS virus agent
CN114246847A (en) Application of chalcone compound in treatment of coronavirus infection
CN113440527A (en) Application of naphthoquine or naphthoquine-containing combined preparation in resisting coronavirus
Rowson et al. STUDIES ON THE MECHANISM OF ACTION OF RILEY VIRUS: II. Action of Substances Affecting the Reticuloendothelial System on the Level of Viraemia
CN114225005A (en) Compound oral syrup capable of effectively inhibiting HIV, HBV, H1N1, H3N2 and nCoV
JP2005500995A (en) Use of Filanthus components for the treatment or prevention of infections caused by hepatitis B virus
CN106619591B (en) The purposes and pharmaceutical composition of oxetacaine in medicine preparation
WO2023089862A1 (en) Stephania cephalantha-derived alkaloid-containing preparation
EP1062947A1 (en) Remedies for aids

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication

Application publication date: 20210126

WW01 Invention patent application withdrawn after publication